68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.

By M. Eder, M. Schäfer, U. Bauder-Wüst, W. Hull, C. Wängler, W. Mier, U. Haberkorn, M. Eisenhut. Bioconjugate chemistry, 2012

820 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 (2017, methodology): “Products: (68)Ga-PSMA-11 [7], (68)Ga-PSMA-617 [42], (68)GaPSMA-I&T [43]; in this manuscript all referred to as (68)GaPSMA Nuclide: [(68)Ga], gallium-68 Dosage/activity: 1.”
Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy (2015, methodology): “COPYRIGHT © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc. 668 THE JOURNAL OF NUCLEAR MEDICINE • Vol. 56 • No. 5 • May 2015 of 68Ga-PSMA (Glu-NH-CO-NH-Lys-(Ahx)-[68Ga(HBED-CC)]) as an extracellular PSMA inhibitor for PET imaging demonstrated a high specificity for PSMA tumor–exp”
Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer (2013, methodology): “(68)Ga was obtained from a (68)Ge/(68)Ga radionuclide generator and complexed with the HBED-CC conjugate as previously published [16, 17].”
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions (2013, methodology): “However, we cannot exclude that the (68)Ga-labelled PSMA ligand as a small molecule [7] redistributes from the intravascular compartment to the interstitial space with time.”